Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan


  • Kathleen L. FuchsEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_517


Avonex®; Betaseron®; Rebif®


Interferon β is a disease-modifying drug currently indicated for treatment of relapsing forms of multiple sclerosis. Its mechanism of action is complex and is presumed to inhibit immune system T-cell activation and migration into the central nervous system as well as modulate the action of some pro-inflammatory proteins (cytokines). There are three FDA approved beta interferons available in the US - Avonex® (INF-β1a), Betaseron® (INF-β1b), and Rebif® (INF-β1a). These medications are administered via injection, and each has been shown to reduce the frequency of MS relapses, reduce MRI evidence of brain lesions, and possibly reduce disability progression.


References and Readings

  1. National Clinical Advisory Board of the National Multiple Sclerosis Society. (2007). Disease management consensus statement. Retrieved 15 Feb 2010, from http://www.nationalmssociety.org/download.aspx?id=8.
  2. Noseworthy, J., Miller, D., & Compston, A. (2006). Disease-modifying treatments in multiple sclerosis. In A. Compston, C. Confavreux, H. Lassman, I. McDonald, D. Miller, J. Noseworthy, et al. (Eds.), McAlpine’s multiple sclerosis (4th ed., pp. 729–802). Philadelphia: Elsevier.CrossRefGoogle Scholar
  3. Zhang, J., Hutton, G., & Zang, Y. (2002). A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clinical Therapeutics, 24, 1998–2021.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Virginia Health SystemCharlottesvilleUSA